Product Description
Mechanisms of Action: ADRA1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Canada | Chile | Ecuador | Greece | Hong Kong | India | Ireland | Italy | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Poland | Romania | Russia | Singapore | Slovenia | South Africa | Sri Lanka | Taiwan | United Kingdom | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|